摘要
肝母细胞瘤(hepatoblastoma,HB)多见于2岁以下婴幼儿,是儿童罕见的恶性实体肿瘤,占儿童肝脏肿瘤的60%~85%,晚期病例预后差。核糖核酸(ribonucleic acid,RNA)N6-methyladenosine(m6A)修饰是真核生物RNA内普遍存在的表观遗传学修饰,广泛参与肿瘤的生物学过程。目前诸多研究发现m6A修饰在HB的发生、发展过程中起关键作用,选用合适检测手段深入研究m6A修饰的分子机制对于HB的诊断、预后评估以及靶向治疗具有重要意义。本文综述m6A修饰在HB中的研究进展,旨在阐明m6A修饰的分子机制及其作为HB生物学标志物和治疗靶点的潜在价值,探索HB的新型诊疗手段。
As a rare malignant solid tumor in children,hepatoblastoma(HB)is more common in infants aged 0 to 2 years,accounting for 60%-85%of pediatric liver tumors.The prognosis of advanced HB is rather poor.RNA m6A(N6-methyladenosine,m6A)is an ubiquitous epigenetic modification in eukaryotic RNA.It is extensively implicated in various biological processes of tumors.Many studies have demonstrated that m6A modification plays some vital roles in the occurrence and development of HB.Therefore selecting appropriate detection methods and elucidating the molecular mechanisms of m6A modification are significant for proper managements of HB.Summarizing the latest researches of m6A modification in HB,this review examined its potential value of biological markers or therapeutic targets for HB and provided rationales for new management tools for HB.
作者
杨丽媛
顾松
王晶
周吉全
Yang Liyuan;Gu Song;Wang Jing;Zhou Jiquan(Department of General Surgery,Shanghai Children's Medical Center,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China)
出处
《临床小儿外科杂志》
CAS
CSCD
2023年第12期1130-1134,共5页
Journal of Clinical Pediatric Surgery
基金
国家自然科学基金(82072375,82172357)
2021年度国家临床重点专科建设项目[沪卫医(2021)99号]
